IL‑33/ST2 pathway in a bleomycin‑induced pulmonary fibrosis model
Jiao Xu1, Jinxu Zheng2, Ping Song2
1Department of Respiratory Medicine, Changzhou Wujin People's Hospital, Changzhou, Jiangsu 213017, P.R. China.
Molecular Medicine Reports
|July 1, 2016
Summary
The interleukin-33/ST2 pathway plays a role in bleomycin-induced pulmonary fibrosis. This study observed increased inflammation and fibrosis markers, implicating the IL-33/ST2 pathway in disease pathogenesis.
Area of Science:
- Immunology
- Pulmonology
- Pathology
Background:
- Pulmonary fibrosis is a debilitating lung disease with complex pathogenesis.
- The interleukin-33 (IL-33)/ST2 signaling pathway is implicated in inflammatory and fibrotic processes.
Purpose of the Study:
- To investigate the role of the IL-33/ST2 pathway in a bleomycin-induced rodent model of acute pulmonary fibrosis.
- To elucidate the pathogenesis of pulmonary fibrosis through the examination of key molecular markers.
Main Methods:
- Pulmonary fibrosis was induced in rats via endotracheal bleomycin administration.
- Histopathological analysis (hematoxylin and eosin, Masson's trichrome staining) assessed injury, inflammation, and fibrosis.
- Western blotting measured protein expression of IL-33, ST2, MyD88, and TRAF6.
- Enzyme-linked immunosorbent assay (ELISA) quantified serum levels of IL-4 and IL-13.
Main Results:
- Bleomycin treatment significantly increased alveolitis and fibrosis scores compared to controls.
- IL-33 expression peaked on day 7, while ST2, MyD88, and TRAF6 showed sustained increases post-bleomycin.
- Serum IL-4 and IL-13 levels were elevated from day 7, peaking on day 28 in the bleomycin group.
Conclusions:
- The IL-33/ST2 signaling pathway is actively involved in the pathogenesis of bleomycin-induced pulmonary fibrosis.
- Elevated levels of IL-33, ST2, MyD88, TRAF6, IL-4, and IL-13 suggest a critical role for this pathway in fibrotic progression.
